Cart
sales@molnova.com
JAK/HDAC-IN-1
CAS No. 2284621-75-4
JAK/HDAC-IN-1( —— )
Catalog No. M24039 CAS No. 2284621-75-4
JAK/HDAC-IN-1 is an effective JAK2/HDAC dual inhibitor (IC50s: 4 and 2 nM for JAK2 and HDAC). It also shows antiproliferative and proapoptotic activities in several hematological cell lines.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 110 | In Stock |
|
| 10MG | 178 | In Stock |
|
| 25MG | 340 | In Stock |
|
| 50MG | 512 | In Stock |
|
| 100MG | 737 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJAK/HDAC-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionJAK/HDAC-IN-1 is an effective JAK2/HDAC dual inhibitor (IC50s: 4 and 2 nM for JAK2 and HDAC). It also shows antiproliferative and proapoptotic activities in several hematological cell lines.
-
DescriptionJAK/HDAC-IN-1 is an effective JAK2/HDAC dual inhibitor (IC50s: 4 and 2 nM for JAK2 and HDAC). It also shows antiproliferative and proapoptotic activities in several hematological cell lines.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC|HDAC2|HDAC6|HDAC8|JAK1|JAK2|JAK3|Tyk2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2284621-75-4
-
Formula Weight450.32
-
Molecular FormulaC19H21Cl2N7O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:20.83 mg/mL (46.26 mM; Need ultrasonic)
-
SMILESONC(CCCCCn1ncc(Nc(nc2)nc(Nc(cc3)ccc3Cl)c2Cl)c1)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Liang X, et al. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. J Med Chem. 2019 Apr 25;62(8):3898-3923.
molnova catalog
related products
-
T326
A potent and selective HDAC3 inhibitor with IC50 of 0.26 uM.
-
1-Naphthohydroxamic ...
1-Naphthohydroxamic acid (Compound 2) is a potent and selective HDAC8 inhibitor with an IC50 of 14 μM, and it is more selectively for HDAC8 than class I HDAC1 and class II HDAC6 (IC50 >100 μM).
-
Encorafenib
LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.
